Clinical trials
Participation clinical trials
Below are recruiting participation clinical trials, each written for real people, not researchers. We’re tracking 2,280 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07024641RecruitingPhase 1
Safety study of GIGA-2339 for chronic Hepatitis B
This study tests an experimental antibody (GIGA-2339) given as an infusion to people with chronic Hepatitis B. It aims to see if the drug is safe and how the body processes it, possibly helping to control the virus.
Chandler, ArizonaAges 18 years+ - NCT07024316RecruitingPhase 1/Phase 2
Oral ciclopirox for skin sensitivity in CEP
This trial tests an oral medication called ciclopirox (ATL-001) to see if it can reduce skin sensitivity to sunlight in adults with CEP. It aims to improve the skin lesions caused by this rare disease.
Cleveland, OhioAges 18 years+ - NCT07027995Recruiting
Food and Fitness with Medicine
This study tests a program that combines nutrition counseling, online grocery support, and exercise sessions for people taking GLP-1 medications. It aims to help manage conditions like high blood pressure, diabetes, high cholesterol, kidney disease, or metabolic syndrome.
Columbus, OhioAges 18 years+ - NCT07027488RecruitingPhase 1
Testing AB821 for advanced solid tumors that resist immunotherapy
This trial tests a new study drug, AB821, for people with advanced solid tumors that have stopped responding to standard treatments, especially immunotherapy. The goal is to see if AB821 can shrink tumors or slow their growth.
New Haven, ConnecticutAges 18 years+ - NCT07014865Recruiting
Quality of life and social participation in multiple myeloma patients and caregivers
This study looks at how multiple myeloma and its treatment affect the daily life, well-being, and social activities of patients and their caregivers. It aims to understand what factors influence their quality of life.
Reggio Emilia, REAges 18 years+ - NCT07020819RecruitingPhase 3
Study of tanruprubart for people with Guillain-Barré syndrome
This trial tests a new medicine, tanruprubart (also called ANX005), for people with Guillain-Barré syndrome. It aims to see if the drug can help improve recovery when given soon after symptoms start.
Phoenix, ArizonaAges 12–85 - NCT07018323RecruitingPhase 2
Study of IMVT-1402 for Graves' disease
This trial tests an investigational drug called IMVT-1402 for people with Graves' disease whose thyroid is still overactive even while taking standard antithyroid medication. The goal is to see if the drug can better control thyroid hormone levels.
Tucson, ArizonaAges 18–75 - NCT07013747RecruitingPhase 1/Phase 2
Acne mRNA vaccine for mild acne
This trial tests an mRNA vaccine designed to treat mild facial acne. It aims to see if the vaccine is safe and effective at reducing acne lesions.
Encino, CaliforniaAges 18–45 - NCT07023627RecruitingPhase 2
New pill for platinum-resistant ovarian cancer with cyclin E1
This study tests a new pill called INCB123667 for people with a type of ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if the drug can shrink tumors or slow their growth.
Mobile, AlabamaAges 18–99 - NCT07015697RecruitingPhase 1
Study of subcutaneous trastuzumab deruxtecan for advanced solid tumors
This trial tests a form of the drug trastuzumab deruxtecan that is given as a shot under the skin for people with certain metastatic solid tumors, including breast cancer and non-small cell lung cancer with HER2 changes. It aims to see how well the shot works and if it is safe.
Newport Beach, CaliforniaAges 18 years+ - NCT07014592Recruiting
Brain activity study in drug-resistant epilepsy patients
This study looks at brain activity in people with epilepsy that does not get better with medicine. Researchers want to record your brain's electrical responses during surgery for your seizures to learn more about how epilepsy works.
Ann Arbor, MichiganAges 22–75 - NCT02685969Recruiting
Brain scan study of amyloid and brain sugar use
This study uses brain imaging to measure two things in the brain—amyloid protein and how the brain uses sugar. It may help researchers better understand early brain changes in people in the ALFA project.
Barcelona, CataloniaAges 45–75 - NCT07010419RecruitingPhase 3
Firmonertinib vs placebo for early-stage lung cancer with rare EGFR mutations
This trial tests if Firmonertinib, a targeted pill, can prevent lung cancer from returning after surgery in people with non-small cell lung cancer that has certain uncommon EGFR gene changes. If you have had complete tumor removal and have one of these specific mutations, this study may help you stay cancer-free longer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07008118RecruitingPhase 1
Study of INCA035784 for certain blood cancers
This trial tests a new drug, INCA035784, for people with myeloproliferative neoplasms (MPNs), a group of blood cancers. It may help if your MPN is called myelofibrosis (MF) or essential thrombocythemia (ET) and has a specific genetic change (CALR mutation), and you've already tried other treatments.
Phoenix, ArizonaAges 18 years+ - NCT07007793RecruitingPhase 3
Study of baxdrostat for primary aldosteronism
This trial tests a new drug called baxdrostat for people with primary aldosteronism, a condition where the adrenal glands make too much aldosterone hormone, often causing high blood pressure. The goal is to see if baxdrostat helps control blood pressure and is safe.
Los Angeles, CaliforniaAges 18 years+ - NCT07007988RecruitingPhase 1
SIM0388 for fluid buildup in the abdomen from cancer
This trial tests a new drug, SIM0388, for people whose cancer has spread and caused fluid buildup in the belly. It aims to see if the drug is safe and can help reduce the fluid.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07007065RecruitingPhase 3
Study of a gene therapy for wet age-related macular degeneration
This trial tests a one-time gene therapy injection for wet AMD that may reduce the need for regular eye injections. It is for people who have already responded to anti-VEGF injections but want a longer-lasting treatment.
Mesa, ArizonaAges 50 years+ - NCT07006688RecruitingPhase 1
Ivosidenib for IDH1-mutated cancers with liver or kidney issues
This trial tests an oral drug (ivosidenib) for people with IDH1-mutated cancers who also have liver or kidney problems. It aims to find the right dose and see how safe and effective it is for these patients.
Atlanta, GeorgiaAges 18 years+ - NCT07005154RecruitingPhase 2
Study of ASP5541 for metastatic prostate cancer
This study tests an experimental drug called ASP5541 for men with metastatic prostate cancer (either hormone-sensitive or castration-resistant). It aims to see if the drug can slow cancer growth and improve outcomes when added to standard hormone therapy.
Huntsville, AlabamaAges 18 years+ - NCT07005713RecruitingPhase 1
Study of tacabrutideg for chronic spontaneous urticaria
This trial tests a new oral medication called tacabrutideg (BGB-16673) for chronic spontaneous urticaria, a condition with frequent hives and itching. It aims to see how safe it is and how well it works, possibly offering a new option for people who still have symptoms despite antihistamines.
Beijing, Beijing MunicipalityAges 18–70 - NCT07005102RecruitingPhase 2/Phase 3
Telisotuzumab adizutecan and osimertinib for EGFR-positive lung cancer
This trial tests a new drug combination (telisotuzumab adizutecan plus osimertinib) as a first treatment for adults with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination is safe and works better than standard care.
Chandler, ArizonaAges 18 years+ - NCT07013201RecruitingPhase 2
Testing a new cream for palmoplantar pustulosis
This trial tests a cream called delgocitinib for people with mild to severe palmoplantar pustulosis (PPP), a skin condition with pustules on the palms and soles. The cream is applied daily for 16 weeks to see if it improves symptoms and is safe.
Fountain Valley, CaliforniaAges 18 years+ - NCT07010159RecruitingPhase 2/Phase 3
Study of KPL-387 for returning pericarditis
This study tests a new medicine, KPL-387, for people whose pericarditis keeps coming back despite standard treatments. It aims to see if this medicine can reduce flare-ups and help you feel better.
Gilbert, ArizonaAges 18–80 - NCT07007637Enrolling by invitationPhase 3
Long-Term Safety and Effectiveness of Sonelokimab for Hidradenitis Suppurativa
This study offers long-term treatment with an investigational biologic, sonelokimab, for people with moderate to severe hidradenitis suppurativa who finished an earlier sonelokimab study. The goal is to see if sonelokimab remains safe and effective over time.
Birmingham, AlabamaAges 12 years+
Hear when a new Participation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for participation?
- Yes. Clin2 currently lists 2,280 recruiting participation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a participation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a participation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.